Roth Capital Downgrades CollaGenex (CGPI) to Hold
CGPI Hot Sheet
Rating Summary:1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Roth Capital downgrades CollaGenex (Nasdaq: CGPI) from Buy to Hold. Price target $16.60.
CollaGenex Pharmaceuticals, Inc. (CollaGenex) together with its subsidiaries, is a specialty pharmaceutical company focused on developing and marketing medical therapies to the dermatology market.
CollaGenex Pharmaceuticals, Inc. (CollaGenex) together with its subsidiaries, is a specialty pharmaceutical company focused on developing and marketing medical therapies to the dermatology market.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- UBS Maintains a 'Buy' on Teva Pharma (TEVA); CEO Highlights From Conference Call
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
